Director Makes Bold Move with Arcutis Biotherapeutics Stock Purchase

New insider activity at Arcutis Biotherapeutics ( (ARQT) ) has taken place on June 17, 2025.

Director Patrick Heron has made a significant investment in Arcutis Biotherapeutics by purchasing 2,646 shares of the company’s stock, valued at $34,609.

Recent Updates on ARQT stock

Arcutis Biotherapeutics recently held its 2025 Annual Meeting of Stockholders, where all proposed matters were approved, including the election of directors and the ratification of its auditor. The company also announced the enrollment of the first child in a Phase 2 study for its ZORYVE cream in infants with atopic dermatitis, and the FDA approved a supplemental New Drug Application for Zoryve topical foam for treating plaque psoriasis. These developments, alongside strong revenue growth and a promising pipeline, have contributed to a positive outlook from analysts, despite challenges such as persistent unprofitability and valuation issues. The FDA approval and the potential market for Zoryve foam are key factors driving the buy rating from analysts.

Spark’s Take on ARQT Stock

According to Spark, TipRanks’ AI Analyst, ARQT is a Neutral.

Arcutis Biotherapeutics scores moderately due to robust revenue growth and promising pipeline developments. However, persistent unprofitability, negative cash flows, and valuation challenges weigh on the score. The mixed technical indicators and positive corporate event contribute modestly to the overall assessment.

To see Spark’s full report on ARQT stock, click here.

More about Arcutis Biotherapeutics

YTD Price Performance: -7.97%

Average Trading Volume: 2,225,178

Technical Sentiment Signal: Buy

Current Market Cap: $1.6B